Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/18716Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Sondhi, Sham M | - |
| dc.contributor.author | Johar, Monika | - |
| dc.contributor.author | Singh, Nirupma | - |
| dc.contributor.author | Dastidar, Sunanda G | - |
| dc.date.accessioned | 2013-06-05T09:34:43Z | - |
| dc.date.available | 2013-06-05T09:34:43Z | - |
| dc.date.issued | 2004-01 | - |
| dc.identifier.issn | 0975-0983(Online); 0376-4699(Print) | - |
| dc.identifier.uri | http://hdl.handle.net/123456789/18716 | - |
| dc.description | 162-167 | en_US |
| dc.description.abstract | A number of biscoupled hemin-thiazoline derivatives 3a-i have been synthesized and screened in vitro against six human cancer cell lines consisting of lung large (NCIH460), colon (HT29), breast (MCF7 and MCF7/ADR), prostate (DU 145) and CNS (U251) tumors. Compound 3e exhibits good anticancer activity against lung large (NCIH460; GI50 4.3MM), where compound 3g shows good anti cancer activity against colon (HT29; GI50 0.9 μM), breast (MCF7; GI50 0.5μM; MCF7/ADR; GI50 1.8μM), prostate (DU 145; GI50 1.6μM) and CNS (U251; GI50 2.5μM) tumors. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | NISCAIR-CSIR, India | en_US |
| dc.rights |  CC Attribution-Noncommercial-No Derivative Works 2.5 India | en_US |
| dc.source | IJC-B Vol.43B(01) [January 2004] | en_US |
| dc.title | Synthesis of biscoupled hemin-thiazoline derivatives and their anticancer activity evaluation | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | IJC-B Vol.43B(01) [January 2004] | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJCB 43B(1) 162-167.pdf | 1.02 MB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.